Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Scheltens

Showing results (801-810 of 903) with videos related to

Pageof 91
Sort By:
Ebiomedicine|September 19, 2025
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled studyOlivier Sol, Julien Mermoud, Merja Hallikainen, et al.
JAMA|July 23, 2009
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairmentNiklas Mattsson, Henrik Zetterberg, Oskar Hansson, et al.
Dementia and Geriatric Cognitive Disorders|May 9, 2013
Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA studyMarinella Damian, Lucrezia Hausner, Katrin Jekel, et al.
Journal of Alzheimer'S Disease : JAD|February 6, 2013
The association between APOE ε4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA StudyAngelique P A Vermeiren, Hans Bosma, Pieter-Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiologyAurore Delvenne, Johan Gobom, Betty Tijms, et al.
Neurology|June 12, 2020
ATN classification and clinical progression in subjective cognitive decline: The SCIENCe projectJarith L Ebenau, Tessa Timmers, Linda M P Wesselman, et al.
Neurology|July 31, 2013
Imaging markers for Alzheimer disease: which vs howGiovanni B Frisoni, Martina Bocchetta, Gael Chételat, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 29, 2017
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imagingYi Mo, Julie Stromswold, Kimberly Wilson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 28, 2016
Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairmentEva Louwersheimer, Steffen Wolfsgruber, Ana Espinosa, et al.
Journal of Geriatric Psychiatry and Neurology|October 25, 2019
Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without DementiaLeonie C P Banning, Eveline P C J Janssen, Renske E G Hamel, et al.
Pageof 91

Showing results (801-810 of 903) with videos related to

Sort By:
Pageof 91
Ebiomedicine|September 19, 2025
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled studyOlivier Sol, Julien Mermoud, Merja Hallikainen, et al.
JAMA|July 23, 2009
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairmentNiklas Mattsson, Henrik Zetterberg, Oskar Hansson, et al.
Dementia and Geriatric Cognitive Disorders|May 9, 2013
Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA studyMarinella Damian, Lucrezia Hausner, Katrin Jekel, et al.
Journal of Alzheimer'S Disease : JAD|February 6, 2013
The association between APOE ε4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA StudyAngelique P A Vermeiren, Hans Bosma, Pieter-Jelle Visser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 14, 2022
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiologyAurore Delvenne, Johan Gobom, Betty Tijms, et al.
Neurology|June 12, 2020
ATN classification and clinical progression in subjective cognitive decline: The SCIENCe projectJarith L Ebenau, Tessa Timmers, Linda M P Wesselman, et al.
Neurology|July 31, 2013
Imaging markers for Alzheimer disease: which vs howGiovanni B Frisoni, Martina Bocchetta, Gael Chételat, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 29, 2017
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imagingYi Mo, Julie Stromswold, Kimberly Wilson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 28, 2016
Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairmentEva Louwersheimer, Steffen Wolfsgruber, Ana Espinosa, et al.
Journal of Geriatric Psychiatry and Neurology|October 25, 2019
Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without DementiaLeonie C P Banning, Eveline P C J Janssen, Renske E G Hamel, et al.
Pageof 91